JP2008505087A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505087A5
JP2008505087A5 JP2007519344A JP2007519344A JP2008505087A5 JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5 JP 2007519344 A JP2007519344 A JP 2007519344A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5
Authority
JP
Japan
Prior art keywords
glucagon
insulin
amount
milliunits
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/022812 external-priority patent/WO2006004696A2/en
Publication of JP2008505087A publication Critical patent/JP2008505087A/ja
Publication of JP2008505087A5 publication Critical patent/JP2008505087A5/ja
Pending legal-status Critical Current

Links

JP2007519344A 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 Pending JP2008505087A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (2)

Publication Number Publication Date
JP2008505087A JP2008505087A (ja) 2008-02-21
JP2008505087A5 true JP2008505087A5 (cg-RX-API-DMAC7.html) 2008-07-31

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519344A Pending JP2008505087A (ja) 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法

Country Status (11)

Country Link
EP (1) EP1778266A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008505087A (cg-RX-API-DMAC7.html)
KR (1) KR20070029276A (cg-RX-API-DMAC7.html)
CN (1) CN101001638A (cg-RX-API-DMAC7.html)
AU (1) AU2005260025A1 (cg-RX-API-DMAC7.html)
CA (1) CA2571030A1 (cg-RX-API-DMAC7.html)
IL (1) IL180361A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06014970A (cg-RX-API-DMAC7.html)
NO (1) NO20070174L (cg-RX-API-DMAC7.html)
WO (1) WO2006004696A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200700708B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5894174B2 (ja) 2010-11-03 2016-03-23 アレコー リミテッド グルカゴンを含む新規組成物
CA2995392C (en) 2015-09-04 2023-08-15 Hailiang Chen Stabilized glucagon solutions
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
US11357829B2 (en) 2017-02-03 2022-06-14 Vanderbilt University Systems, compositions and methods for treating diabetes
JP2020527396A (ja) * 2017-07-14 2020-09-10 ゼリス ファーマシューティカルズ インコーポレイテッド 先天性高インスリン症を処置する方法
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
AU2021297529A1 (en) * 2020-06-26 2022-09-22 Xeris Pharmaceuticals, Inc. Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
BR0316327A (pt) * 2002-11-18 2005-09-27 Pfizer Prod Inc Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
KR20050086948A (ko) * 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
Whitehead et al. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery
AU2015204491B2 (en) Rapid action insulin formulations and pharmaceutical delivery systems
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2014524480A5 (cg-RX-API-DMAC7.html)
JP2019517542A5 (cg-RX-API-DMAC7.html)
JP2021503468A5 (cg-RX-API-DMAC7.html)
JP2005501110A5 (cg-RX-API-DMAC7.html)
JP2005520778A5 (cg-RX-API-DMAC7.html)
CN103167878A (zh) 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
ME01546B (me) Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2
CA2971440C (en) Method and compositions for dissolving or solubilizing therapeutic agents
JP2018509419A5 (cg-RX-API-DMAC7.html)
JP2020500864A5 (cg-RX-API-DMAC7.html)
JP2008505087A5 (cg-RX-API-DMAC7.html)
Becker et al. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes
JP2008517991A5 (cg-RX-API-DMAC7.html)
EP3678643B1 (en) Sublingual epinephrine tablets
CN114423461B (zh) 组合
Bush Intensive diabetes therapy and body weight: focus on insulin detemir
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Wu et al. Dipeptidyl peptidase IV (DPP IV): a novel emerging target for the treatment of type 2 diabetes
Mannucci et al. Back to glycemic control: an alternative look at the results of cardiovascular outcome trials in type 2 diabetes
JP2011105610A5 (cg-RX-API-DMAC7.html)